Gregory Frost, PhDCEO at F1 Oncology
Dr. Frost currently serves as Chairman and CEO of F1 Oncology, Inc, a multinational oncology biotechnology company. Previously, he headed the Health Sector of Intrexon Corporation. From 1999 to 2014, Dr. Frost was at Halozyme Therapeutics (NASDAQ HALO), a San Diego public biotechnology company he co-founded, focused on oncology biologics and medication delivery through multiple product approvals, where he served on the Board of Directors and in numerous operational roles, including Chief Scientific Officer since 2002, and CEO since 2010. He has published multiple peer-reviewed articles in the field and is an inventor on key patents supporting approved biologics that have been launched in over 100 countries. Dr. Frost is a member of the American Society of Clinical Oncology, the American Association for Cancer Research and is registered to practice before the U.S. Patent and Trademark Office. Dr. Frost earned his B.A. in biochemistry and molecular biology from the University of California, Santa Cruz, his Ph.D. in the Department of Pathology at the University of California, San Francisco and postdoctoral research at the Sidney Kimmel Cancer Center. As an entrepreneur, Dr. Frost brought the founding platform technologies to Halozyme and secured the initial capital for the company. His current investments through F1 Bioventures LLC span from private to public equities. Dr. Frost serves on the Board of directors of BioCom, a member-driven organization serving life science community of Southern California, F1 Oncology Inc, EXUMA Biotechology SEZC and BioAtla LLC.